UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Cancer cell, 2005-02, Vol.7 (2), p.129-141

2005

Volltextzugriff (PDF)

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations

Hematology reports, 2023-12, Vol.15 (4), p.608-626

2023

Volltextzugriff (PDF)

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma

Cancers, 2024-04, Vol.16 (7), p.1319

2024

Volltextzugriff (PDF)

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

MedComm (2020), 2023-06, Vol.4 (3), p.e254-n/a

2023

Volltextzugriff (PDF)

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Blood cancer journal (New York), 2022-07, Vol.12 (7), p.110-110, Article 110

2022

Volltextzugriff (PDF)

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

Cancers, 2020-12, Vol.13 (1), p.7

2020

Volltextzugriff (PDF)

The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis

Genes & development, 2006-03, Vol.20 (6), p.675-688

2006

Volltextzugriff (PDF)

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia

Leukemia research, 2015-11, Vol.39 (11), p.1299-1308

2015

Volltextzugriff (PDF)

BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation

Cell death and differentiation, 2024-07, Vol.31 (7), p.868-880

2024

Volltextzugriff (PDF)

ARG tyrosine kinase activity is inhibited by STI571

Blood, 2001-04, Vol.97 (8), p.2440-2448

2001

Volltextzugriff (PDF)

The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development

Blood, 2007-11, Vol.110 (10), p.3618-3623

2007

Volltextzugriff (PDF)

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

The Journal of clinical investigation, 2007-03, Vol.117 (3), p.730-738

2007

Volltextzugriff (PDF)

Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Nature medicine, 2024-04, Vol.30 (4), p.1214-1214

2024

Volltextzugriff (PDF)

Current therapies under investigation for COVID-19: potential COVID-19 treatments

Canadian journal of physiology and pharmacology, 2020-08, Vol.98 (8), p.483-489

2020

Volltextzugriff (PDF)

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

Leukemia, 2020-02, Vol.34 (2), p.625-629

2020

Volltextzugriff (PDF)

A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia

Molecular & cellular proteomics, 2010-05, Vol.9 (5), p.780-790

2010

Volltextzugriff (PDF)

3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

Leukemia & lymphoma, 2021-08, Vol.62 (10), p.2457-2465

2021

Volltextzugriff (PDF)

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming

Oncotarget, 2017-09, Vol.8 (40), p.67639-67650

2017

Volltextzugriff (PDF)

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

Leukemia, 2015-01, Vol.29 (1), p.27-37

2015

Volltextzugriff (PDF)

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

Patient preference and adherence, 2023-11, Vol.17, p.2805-2819

2023

Volltextzugriff (PDF)

Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

Leukemia, 2020-09, Vol.34 (9), p.2543-2543

2020

Volltextzugriff (PDF)

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition

Oncotarget, 2017-12, Vol.8 (66), p.109973-109984

2017

Volltextzugriff (PDF)

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin

Blood, 2002-11, Vol.100 (10), p.3767-3775

2002

Volltextzugriff (PDF)

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

Oncotarget, 2017-08, Vol.8 (32), p.52026-52044

2017

Volltextzugriff (PDF)

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

Cancer research (Chicago, Ill.), 2005-10, Vol.65 (19), p.8968-8974

2005

Volltextzugriff (PDF)

1 – 25 von 959

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(860)
Mit Volltextzugriff
(817)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(481)
Life Sciences & Biomedicine
(318)
Physical Sciences
(123)
Biological And Medical Sciences
(110)
Animals
(88)
Technology
(80)
Fundamental And Applied Biological Sciences. Psychology
(67)
Physics
(61)
Exact Sciences And Technology
(57)
Engineering
(53)
Medical Sciences
(48)
Mice
(48)
Agriculture
(45)
Biochemistry & Molecular Biology
(43)
Agronomy
(42)
Plant Sciences
(42)
Engineering, Electrical & Electronic
(35)
Physics, Applied
(33)
Phytopathology. Animal Pests. Plant And Forest Protection
(33)
Herbicides
(32)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(499)
NUS Single-Journal Subscriptions
(331)
IngentaConnect
(274)
Journals@Ovid
(223)
JSTOR All Journals
(129)
ScienceDirect
(119)
MEDLINE
(116)
Wiley-Blackwell Journals
(97)
IngentaConnect Journals
(97)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(58)
Cambridge Journals Online (DEFF)
(57)
Wiley Online Library
(52)
IEEE
(45)
Nature Journals
(40)
SpringerLink (full text journal articles and electronic books)
(40)
Taylor & Francis
(33)
Nexis Uni
(31)
Taylor & Francis Journals Auto-Holdings Collection
(31)
Taylor & Francis Online
(28)
Ebook Central Perpetual and DDA
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia

BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation

ARG tyrosine kinase activity is inhibited by STI571

The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

Current therapies under investigation for COVID-19: potential COVID-19 treatments

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia

3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

Aktive Filter

Suchergebnisse filtern